Table 4. Characteristics of Responders.
| Acc # | 41 | 17 | 27 | 22 | 14 | 63 | 80 |
| Age | 55 | 56 | 59 | 62 | 46 | 48 | 45 |
| Gender | M | M | F | M | F | M | M |
| Performance status | 1 | 2 | 1 | 0 | 2 | 1 | 1 |
| Prognostic group | Intermediate | Poor | Favorable | Intermediate | Intermediate | Favorable | Favorable |
| Prior therapy | IFN | IL-2; Bay43-9006 | IL-2 + Thalidomide + GMSCF | IFN; High-dose IL-2 | High-dose IL-2 | IFN + Thalidomide; High-dose IL-2; Bay 43-9006 | IFN |
| Prior nephrectomy | No | Yes | Yes | Yes | Yes | Yes | Yes |
| Pathology | Conventional | Conventional | Conventional | Conventional | Conventional | Conventional | Conventional |
| Metastatic site(s) | Lymph nodes; adrenal glands | Liver; bone; pleura | Lungs | Lungs | Lungs | Lungs; lymph nodes | Lungs |
| Treatment duration (wks) | 19 | 99 | 63 | 57 | 30 | 29 | 52 |
| Response duration (wks) | 16+ | 195+ | 56 | 183+ | 27 | 25+ | 92 |